The
Shimaoka Lab studies
how to manipulate leukocyte
functions to cure inflammatory diseases.
We Want to Know How to Halt
Only Aberrant Cells.
Dan Peer, a postdoc in the Shimaoka lab, exploits AL-57 to selectively target activated leukocytes. Dan has developed Integrin LFA-1-targeted protamine fusion proteins to deliver siRNAs to leukocytes in vivo ... (view more about this story).
Dan Peer, a postdoc in the Shimaoka lab, exploits AL-57 to selectively target activated leukocytes. Dan has developed Integrin LFA-1-targeted protamine fusion proteins to deliver siRNAs to leukocytes in vivo ... (view more about this story).
We Want to Know How Cells
Migrate in Inflammation.
Eun Jeong Park, a postdoc in the Shimaoka lab, has found that not only up-regulation but also down-regulation of integtrin adhesiveness represents an important mechanism to facilitate lymphocyte migration... (view more about this story).
Eun Jeong Park, a postdoc in the Shimaoka lab, has found that not only up-regulation but also down-regulation of integtrin adhesiveness represents an important mechanism to facilitate lymphocyte migration... (view more about this story).
We Want to Use Integrins to
Boost RNAi Medicine
The Shimaoka lab developed I-tsNP, the integrin-targeted stabilized nanoparticle to manipulate gene expression of leukocytes with siRNA in vivo. The work is featured in the Science's Perspectives, "The Art of Assembly". This powerful technology lead to the discovery of cyclin D1 as a novel anti-inflammation target... (view more about this story).
The Shimaoka lab developed I-tsNP, the integrin-targeted stabilized nanoparticle to manipulate gene expression of leukocytes with siRNA in vivo. The work is featured in the Science's Perspectives, "The Art of Assembly". This powerful technology lead to the discovery of cyclin D1 as a novel anti-inflammation target... (view more about this story).
Updated on May 28, 2008
Integrin-targeted nanoparticle entrapping
siRNAs